Tags

Type your tag names separated by a space and hit enter

Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications.
Schizophr Res 2004; 66(2-3):163-7SR

Abstract

OBJECTIVE

To examine the impact of smoking status on antipsychotic-associated weight gain.

METHOD

In two double-blind studies, 552 adult and elderly patients with schizophrenia or schizoaffective disorder were randomly assigned to risperidone or olanzapine treatment for 8 weeks. Smoking status at baseline was recorded together with other background characteristics.

RESULTS

In both adult and elderly patients, olanzapine-treated smokers and nonsmokers gained weight at a similar rate, whereas risperidone-treated smokers gained less weight than did nonsmokers. Olanzapine was associated with significantly greater weight gain than was risperidone across all measures in both adult and elderly patients.

CONCLUSION

These findings support a quantitatively or qualitatively different effect of risperidone and olanzapine on the metabolic changes underlying antipsychotic-associated weight gain. Mechanisms responsible for olanzapine's effect on weight appear to counteract smokers' physiologic bias toward weight loss, an effect not seen among risperidone-treated patients.

Authors+Show Affiliations

CNS Medical Affairs, Janssen Pharmaceutica Products, LP, 1125 Trenton-Harbourton Road, Titusville, NJ 08560-0200, USA. rlasser@janus.jnj.com

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15061249

Citation

Lasser, Robert A., et al. "Smokers and Nonsmokers Equally Affected By Olanzapine-induced Weight Gain: Metabolic Implications." Schizophrenia Research, vol. 66, no. 2-3, 2004, pp. 163-7.
Lasser RA, Mao L, Gharabawi G. Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications. Schizophr Res. 2004;66(2-3):163-7.
Lasser, R. A., Mao, L., & Gharabawi, G. (2004). Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications. Schizophrenia Research, 66(2-3), pp. 163-7.
Lasser RA, Mao L, Gharabawi G. Smokers and Nonsmokers Equally Affected By Olanzapine-induced Weight Gain: Metabolic Implications. Schizophr Res. 2004 Feb 1;66(2-3):163-7. PubMed PMID: 15061249.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications. AU - Lasser,Robert A, AU - Mao,Lian, AU - Gharabawi,Georges, PY - 2002/12/02/received PY - 2003/04/29/revised PY - 2003/05/01/accepted PY - 2004/4/6/pubmed PY - 2004/5/5/medline PY - 2004/4/6/entrez SP - 163 EP - 7 JF - Schizophrenia research JO - Schizophr. Res. VL - 66 IS - 2-3 N2 - OBJECTIVE: To examine the impact of smoking status on antipsychotic-associated weight gain. METHOD: In two double-blind studies, 552 adult and elderly patients with schizophrenia or schizoaffective disorder were randomly assigned to risperidone or olanzapine treatment for 8 weeks. Smoking status at baseline was recorded together with other background characteristics. RESULTS: In both adult and elderly patients, olanzapine-treated smokers and nonsmokers gained weight at a similar rate, whereas risperidone-treated smokers gained less weight than did nonsmokers. Olanzapine was associated with significantly greater weight gain than was risperidone across all measures in both adult and elderly patients. CONCLUSION: These findings support a quantitatively or qualitatively different effect of risperidone and olanzapine on the metabolic changes underlying antipsychotic-associated weight gain. Mechanisms responsible for olanzapine's effect on weight appear to counteract smokers' physiologic bias toward weight loss, an effect not seen among risperidone-treated patients. SN - 0920-9964 UR - https://www.unboundmedicine.com/medline/citation/15061249/Smokers_and_nonsmokers_equally_affected_by_olanzapine_induced_weight_gain:_metabolic_implications_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0920996403001531 DB - PRIME DP - Unbound Medicine ER -